Michael F. Mahoney has been the CEO of Boston Scientific Corp. since 2011, steering the company towards innovative medical device solutions. He has a strong background in the medical field, previously holding senior roles at Johnson & Johnson. With a finance degree from the University of Iowa and an MBA from Wake Forest University, he combines technical knowledge with a business mind. Mahoney owns over $109 million in Boston Scientific shares, highlighting his belief in the company’s future. His annual pay in 2023 was over $18 million, which included a base salary of $1.4 million and performance bonuses. In his time as CEO, he has focused on driving growth and maximizing shareholder value while maintaining a rigorous performance-based compensation system. Under his leadership, Boston Scientific has navigated significant market challenges and emerged stronger, emphasizing long-term sustainability. Mahoney is also prepared for changes, with solid severance plans in place. A leader who values performance, he continues to drive Boston Scientific in its mission to deliver less invasive healthcare solutions around the globe.

Quick Links

Michael F. Mahoney

CEO of Boston Scientific

Education

Finance degree from the University of Iowa and an M.B.A. from Wake Forest University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

April 1, 1965 - 60 years ago

CEO of Boston Scientific for

12 years 8 months (Nov 2012 - Present)

Previous Experience

President of Johnson & Johnson's DePuy Orthopaedics

Rivals

Competitors/colleagues of Michael F. Mahoney

Samuel N. Hazen

CEO of HCA Healthcare

2023 Compensation

Stock

$24.94M

Salary

$1.51M

Bonus

$5.03M

Other

$577.42K

Total Holdings

$24.51M

Joseph M. Hogan

CEO of Align Technology

2022 Compensation

Stock

$3.72M

Salary

$1.29M

Bonus

$0.00

Other

$17.73K

Total Holdings

$45.19M

Javier J. Rodriguez

CEO of DaVita

2022 Compensation

Stock

$0.00

Salary

$1.20M

Bonus

$0.00

Other

$610.78K

Total Holdings

$133.24M

Joseph W. Dziedzic

CEO of Integer Holdings

2022 Compensation

Stock

$0.00

Salary

$1.23M

Bonus

$0.00

Other

$97.75K

Total Holdings

$34.74M

Christophe Beck

CEO of Ecolab

2023 Compensation

Stock

$2.21M

Salary

$1.24M

Bonus

$3.73M

Other

$445.83K

Total Holdings

$31.72M

Holdings

See how much did Michael F. Mahoney make over time.

Michael F. Mahoney holds over $109 million in Boston Scientific stock, a significant investment that reflects his commitment to the company. Over the past few years, his stock value has seen fluctuations typical in the medical device sector. Although his wealth peaked during 2022, with stock values rising amid strong company performance, it has stabilized somewhat since then. His holdings peaked in 2023 due to a successful year for the company, resulting in substantial stock vesting. Despite market challenges, Mahoney's stake remains a large part of his financial portfolio, indicating his trust in Boston Scientific and its future growth. The value of his holdings is an important part of his overall compensation and showcases the alignment between his interests and those of shareholders. He continues to retain a substantial amount of his wealth in company shares, which speaks to his belief in Boston Scientific's ongoing mission and capabilities.

Total Stock Sold

$157.28M

BSX

$157.28M

3,490,522 BSX shares

What if they kept their stock?

If Michael F. Mahoney didn't sell their stock, today they would have:
Extra BSX3,490,522 shares worth $124.23M.
This is -21.02% and $33.06M less than what they got when they sold the stock.

Charitable Transactions

BSX

1,021,385 shares

BSX

Recent Charitable Transactions

BSX

7,800 shares

BSX

Nov 26, 2024

Charity

BSX

176,245 shares

BSX

Aug 30, 2024

Charity

BSX

318,218 shares

BSX

Aug 30, 2023

Charity

BSX

365,457 shares

BSX

Sep 6, 2022

Charity

BSX

34,900 shares

BSX

Jan 1, 2022

Charity

BSX

34,965 shares

BSX

Jul 6, 2021

Charity

Insider Trading

See recent insider trades of Michael F. Mahoney.

BSX

260,236 shares

BSX

Feb 11, 2025

Received

BSX

7,800 shares

BSX

Nov 26, 2024

Charity

BSX

$13.83M

BSX at $84.96/share

Nov 5, 2024

Sale

BSX

$13.78M

BSX at $84.63/share

Oct 7, 2024

Sale

BSX

$13.21M

BSX at $81.17/share

Sep 5, 2024

Sale

BSX

209,278 shares

BSX

Aug 30, 2024

Charity

BSX

176,245 shares

BSX

Aug 30, 2024

Charity

CVS

$500.29K

CVS at $54.49/share

May 2, 2024

Purchase

BSX

146,666 shares

BSX

Feb 6, 2024

Received

Compensation History

See how much did Michael F. Mahoney make over time.

In 2023, Michael F. Mahoney's total compensation exceeded $18 million, showcasing his substantial leadership role at Boston Scientific. This package included a $1.4 million base salary, a performance-oriented bonus of $3.2 million, and approximately $6.6 million in vested stock. Notably, his compensation is closely tied to the company’s performance metrics, aligning his goals with that of integrity towards shareholders. Mahoney’s pay plan reflects a strong emphasis on rewarding results, with a significant portion of his total earnings varying based on the company's financial success. This compensation strategy aims to motivate Mahoney and the leadership team to achieve long-term goals. His leadership style encourages high performance, ensuring that the team is always focused on driving growth and value in a competitive market. He’s also safeguarded by severance policies that protect him in instances of company restructuring, demonstrating his secure position within the organization.

Year

2023

Total Compensation

$11.53M

Salary

$1.40M

Board Justification

The compensation philosophy emphasizes pay for performance, aligning executive compensation with the company's performance and long-term shareholder value.

Bonus

$3.24M

Board Justification

The actual amount earned by Mr. Mahoney under the 2023 Annual Bonus Plan is based on Company performance against financial metrics and individual performance objectives, resulting in a payout of 150% of the target award opportunity.

Other

$190.18K

Board Justification

Other compensation includes matching contributions to the 401(k) plan, personal use of corporate aircraft, term life insurance, and financial planning services.

Restricted Stock

$6.69M(143.98K RSU)

Board Justification

The stock awards that vested in 2023 include performance-based RSUs that were earned based on the company's performance metrics, specifically 200% of the target number of rTSR performance-based RSUs due to the company's performance ranking in the 90th percentile relative to peers.

Performance Metrics

The performance metrics for 2023 included adjusted net sales, adjusted EPS, and ESG targets.

Other Boston Scientific CEOs

Here are other CEOs of Boston Scientific

Hank Kucheman

Ex-CEO of Boston Scientific

December 2011 - November 2012